Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page’s displayed site revision/version was updated from v3.5.2 to v3.5.3, reflecting a change to the ClinicalTrials.gov interface build rather than the study record content.SummaryDifference0.0%

- Check19 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check27 days agoChange DetectedPublication added to the Publications section: Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis, Paediatr Drugs, 2026 Apr 2 (Online ahead of print).SummaryDifference0.0%

- Check34 days agoChange DetectedAdded a new publication citation to the Publications section: 'Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis' Am J Clin Dermatol. 2026 Mar 28.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.4.2 to v3.5.0.SummaryDifference0.0%

- Check84 days agoChange Detected- Revision label updated from v3.4.1 to v3.4.2. No substantive content changes to the page.SummaryDifference0.0%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.